Viking Therapeutics, Inc. (NASDAQ:VKTX - Get Free Report) COO Marianna Mancini sold 281,425 shares of the company's stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $78.66, for a total transaction of $22,136,890.50. Following the sale, the chief operating officer now directly owns 348,508 shares in the company, valued at $27,413,639.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Viking Therapeutics Stock Performance
VKTX stock opened at $75.76 on Friday. The company's 50 day moving average is $71.60 and its 200 day moving average is $36.78. Viking Therapeutics, Inc. has a 1-year low of $8.28 and a 1-year high of $99.41.
Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last posted its quarterly earnings data on Wednesday, April 24th. The biotechnology company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.01. During the same quarter in the prior year, the firm earned ($0.25) earnings per share. Research analysts forecast that Viking Therapeutics, Inc. will post -1.08 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years
From Banyan Hill Publishing | Ad
If you think AI is big, then you have got to check out something I call Imperium…
By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)
Watch my video for all of the details
Several institutional investors have recently modified their holdings of the stock. Perpetual Ltd bought a new position in Viking Therapeutics during the first quarter valued at approximately $78,586,000. American Century Companies Inc. grew its position in Viking Therapeutics by 59.6% during the third quarter. American Century Companies Inc. now owns 2,202,228 shares of the biotechnology company's stock valued at $24,379,000 after acquiring an additional 822,156 shares during the last quarter. Massachusetts Financial Services Co. MA bought a new position in Viking Therapeutics during the fourth quarter valued at approximately $12,341,000. Goldman Sachs Group Inc. grew its position in Viking Therapeutics by 88.3% during the fourth quarter. Goldman Sachs Group Inc. now owns 1,119,885 shares of the biotechnology company's stock valued at $20,841,000 after acquiring an additional 525,296 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in Viking Therapeutics by 194.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 765,320 shares of the biotechnology company's stock valued at $8,472,000 after acquiring an additional 505,578 shares during the last quarter. 76.03% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
Several equities research analysts have commented on the stock. StockNews.com raised shares of Viking Therapeutics to a "sell" rating in a report on Thursday, April 25th. Truist Financial upped their price objective on shares of Viking Therapeutics from $32.00 to $120.00 and gave the company a "buy" rating in a report on Thursday, February 29th. BTIG Research upped their price target on Viking Therapeutics from $100.00 to $125.00 and gave the company a "buy" rating in a research report on Tuesday, March 26th. Maxim Group reiterated a "buy" rating and set a $120.00 price target on shares of Viking Therapeutics in a research report on Friday, March 15th. Finally, William Blair reiterated an "outperform" rating on shares of Viking Therapeutics in a research report on Friday, February 23rd. One investment analyst has rated the stock with a sell rating and ten have given a buy rating to the company. According to MarketBeat.com, Viking Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $112.25.
Get Our Latest Stock Report on VKTX
About Viking Therapeutics
(
Get Free Report)
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
